CD33 TRAILBody - TRIO Pharmaceuticals
Latest Information Update: 20 Aug 2024
Price :
$50 *
At a glance
- Originator Trio Pharmaceuticals
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action CD33 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia; Myelodysplastic syndromes
Most Recent Events
- 26 Jul 2024 Preclinical trials in Acute myeloid leukaemia in USA (Parenteral) (TRIO Pharmaceuticals pipeline, July 2024)
- 26 Jul 2024 Preclinical trials in Myelodysplastic syndromes in USA (Parenteral) (TRIO Pharmaceuticals pipeline, July 2024)